ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > FDA’s Decision to Approve New Treatment for Alzheimer’s Dise

<< Previous

Bullboard Posts

Next >>

Comment by M101on Jun 07, 2021 1:56pm

113 Views

Post# 33341250

RE:RE:RE:RE:RE:FDA’s Decision to Approve New Treatment for Alzheimer’s Dise

Mole101 wrote:
Drug companies are required to conduct post-approval studies...

You can only laugh at the level of regulatory capture implied: Patients will now be required to fund the reasearch for the benefit of the company, providing the company is willing to continue doing it.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing